Please wait a minute...
文章检索
预防医学  2020, Vol. 32 Issue (12): 1208-1212    DOI: 10.19485/j.cnki.issn2096-5087.2020.12.005
  论著 本期目录 | 过刊浏览 | 高级检索 |
凝血酶激活的纤溶抑制物与冠心病关系研究
赵梦男1, 田沛茹2, 邱莉3, 李雨宁1, 王晓楠1, 易博禹1, 时景璞1
1.中国医科大学附属第一医院临床流行病与循证医学教研室,辽宁 沈阳 110001;
2.赤峰市医院慢病管理中心;
3.抚顺市中心医院
The relationship between thrombin activatable fibrinolysis inhibitor and coronary heart disease
ZHAO Mengnan*, TIAN Peiru, QIU Li, LI Yuning, WANG Xiaonan, YI Boyu, SHI Jingpu
*Department of Clinical Epidemiology and Evidence-based Medicine, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China
全文: PDF(1034 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 分析凝血酶激活的纤溶抑制物(TAFI)水平与冠心病的关系,为防制冠心病提供依据。方法 选取辽宁省抚顺市中心医院住院治疗的冠心病患者为病例组,选取该院同期住院的非冠心病患者为对照组,收集研究对象的人口学信息和TAFI、血脂、血糖等实验室检测资料,采用Logistic回归模型分析TAFI水平与冠心病的关系。结果 纳入病例组和对照组各222例,年龄中位数分别为62岁和57岁。冠心病临床类型为稳定型心绞痛100例,不稳定型心绞痛44例,急性心肌梗死78例。多因素Logistic回归分析结果显示,TAFI>22.88 μg/mL(对照组TAFI浓度的第75百分位数)与冠心病患病存在统计学关联(OR=1.619,95%CI:1.011~2.593);TAFI>22.88 μg/mL与不稳定型心绞痛(OR=2.917,95%CI:1.433~5.939)、急性心肌梗死(OR=2.626,95%CI:1.007~6.847)存在统计学关联。结论 高水平TAFI与不稳定型心绞痛和急性心肌梗死有关。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
赵梦男
田沛茹
邱莉
李雨宁
王晓楠
易博禹
时景璞
关键词 凝血酶激活的纤溶抑制物冠心病病例对照研究    
AbstractObjective To analyze the relationship between thrombin activatable fibrinolysis inhibitor ( TAFI ) and coronary heart disease ( CHD ), and to provide evidence for the prevention of CHD. Methods The patients with CHD in Fushun Central Hospital in Liaoning Province were selected as the case group, the patients without CHD in the same hospital and period were selected as the control group. The demographic information and clinical examination results ( serum TAFI, lipid, glucose, etc. ) were collected to analyze the association between TAFI and CHD by logistic regression models.The multivariate logistic regression analysis was used to explore the relationship between TAFI and CHD. Results There were 222 cases, including 100 cases of stable angina, 44 cases of unstable angina and 78 cases of acute myocardial infarction, and 222 controls. The median ages of cases and controls were 62 and 57 years old. The results of multivariate logistic regression analysis showed that serum TAFI>22.88 μg/mL ( P75 of controls ) was associated with the risk of CHD ( OR=1.619, 95%CI: 1.011-2.593 ), unstable angina ( OR=2.917, 95%CI: 1.433-5.939 ) and acute myocardial infarction ( OR=2.626, 95%CI: 1.007-6.847 ). Conclusion The high level of TAFI is related to CHD, unstable angina and acute myocardial infarction.
Key wordsthrombin activatable fibrinolysis inhibitor    coronary heart disease    case-control study
收稿日期: 2020-07-15      修回日期: 2020-08-29     
中图分类号:  R541.4  
通信作者: 时景璞,E-mail:sjp562013@126.com   
作者简介: 赵梦男,硕士在读
引用本文:   
赵梦男, 田沛茹, 邱莉, 李雨宁, 王晓楠, 易博禹, 时景璞. 凝血酶激活的纤溶抑制物与冠心病关系研究[J]. 预防医学, 2020, 32(12): 1208-1212.
ZHAO Mengnan, TIAN Peiru, QIU Li, LI Yuning, WANG Xiaonan, YI Boyu, SHI Jingpu. The relationship between thrombin activatable fibrinolysis inhibitor and coronary heart disease. Preventive Medicine, 2020, 32(12): 1208-1212.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2020.12.005      或      http://www.zjyfyxzz.com/CN/Y2020/V32/I12/1208
[1] 胡盛寿,杨跃进,郑哲,等.《中国心血管病报告2018》概要[J].中国循环杂志,2019,34(3):209-220.
[2] YILDIRIM M N,SELCOKI Y,UYSAL S,et al.Thrombin activatable fibrinolysis inhibitor:its role in slow coronary flow[J].Herz,2014,39(8):993-1000.
[3] BRIDGE K I,BOLLEN L,ZHONG J,et al.Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease[J]. J Thromb Haemost,2017,15(11):2218-2225.
[4] PLUG T,MEIJERS J C.Structure-function relationships in thrombin-activatable fibrinolysis inhibitor[J]. J Thromb Haemost,2016,14(4):633-644.
[5] 江明华,吴连拼,陶红群,等. 汉族人凝血酶活化的纤溶抑制物编码区的基因多态性与冠状动脉粥样硬化性心脏病相关性研究[J].中华检验医学杂志,2007,30(9):1017-1022.
[6] 中华医学会心血管病学分会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206.
[7] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2015,43(5):380-393.
[8] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)[J].中华心血管病杂志,2017,45(5):359-376.
[9] DAI H X,SHI J P,HE Q,et al.Dose-response relationship between thrombin-activatable fibrinolysis inhibitor (TAFI) and stroke:a Chinese case-control study[J]. Med Sci Monit,2017,23:4376-4381.
[10] SCHROEDER V,CHATTERJEE T,MEHTA H,et al.Thrombin activatable fibrinolysis inhibitor(TAFI)levels in patients with coronary artery disease investigated by angiography[J].Thromb Haemost,2008,88(7):1020-1025.
[11] BOFFA M B,NESHEIM M E,KOSCHINSKY M L.Thrombin activable fibrinolysis inhibitor(TAFI):molecular genetics of an emerging potential risk factor for thrombotic disorders[J].Curr Drug Targets Cardiovasc Haematol Disord,2001,1(2):59-74.
[12] LEUNG L L,MYLES T,NISHIMURA T,et al.Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B(or TAFI)[J].Mol Immunol,2008,45(16):4080-4083.
[13] 吴连拼,江明华,黄明远,等.急性冠脉综合征患者pentraxin-3与凝血酶活化的纤溶抑制物的变化[J].心脑血管病防治,2012,12(6):447-448.
[14] DE BRUIJNE E L E,GILS A,GUIMARÃES A H C,et al.The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age:the ATTAC study[J]. J Thromb Haemost,2009,7(6):919-927.
[15] 梁红英,邝开安,张淑玲.心肌梗死患者凝血酶激活纤溶抑制物与纤维蛋白原的关系研究[J].实用心脑肺血管病杂志,2011,19(1):83.
[16] 张铭朋,刘向群,许玲,等.老年不稳定性心绞痛患者血浆凝血酶激活纤溶抑制物的变化及低分子量肝素的治疗作用[J].中国老年学杂志,2007,27(17):1688-1690.
[17] 李桂艳,李萍,贾明利,等.凝血酶激活纤溶抑制物散射比浊法检测结果临床应用评估[J].临床军医杂志,2016,44(10):1059-1061.
[18] PAOLA C A,ANTONUCCI E,LIOTTA A A,et al.TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit[J]. Thromb Res,2006,118(4):495-500.
[1] 张媛, 韩正风, 马艳. 老年人群肌少症危险因素的病例对照研究[J]. 预防医学, 2023, 35(6): 461-464.
[2] 韩俊丽, 刘洋, 高大维, 孙婕, 徐鹏鹏, 龚天麒, 胡颉颖, 曹艳宏, 吕勇. 耶尔森菌病危险因素的病例对照研究[J]. 预防医学, 2023, 35(2): 93-98.
[3] 高波, 赵磊. 鄞州区四种主要慢性病流行特征分析[J]. 预防医学, 2021, 33(8): 822-824.
[4] 李媛媛, 苏银霞, 罗坤, 胡晓媛, 刘波, 王育珊, 姚华. 墨玉县维吾尔族居民冠心病患病现状及影响因素分析[J]. 预防医学, 2021, 33(12): 1265-1268,1272.
[5] 舒铭铭, 潘兴强, 张百蕾, 黄芳, 张婧, 洪菱, 蔡婕. 被动吸烟与妊娠糖尿病的关联分析[J]. 预防医学, 2020, 32(7): 726-729.
[6] 钟荣万, 王亚妮. 冠心病急性事件报告发病的圆形分布法分析[J]. 预防医学, 2020, 32(6): 595-598.
[7] 任艳军, 张铁威, 刘庆敏, 赵刚, 陆凤, 龚巍巍, 俞敏. 杭州市居民膳食模式与甲状腺癌的病例对照研究[J]. 预防医学, 2020, 32(11): 1081-1085.
[8] 金玫华, 李婧, 刘小琦, 陈琳, 杨中荣. 湖州市HIV/AIDS分子网络传播簇的影响因素研究[J]. 预防医学, 2020, 32(10): 992-995.
[9] 朱蔚, 胡健伟, 冯佩, 喻茜, 刘丽. 血清尾加压素水平与妊娠高血压的关系研究[J]. 预防医学, 2020, 32(1): 68-70.
[10] 方益荣, 马岩, 许树红, 裴迎新. 肺癌危险因素的病例对照研究[J]. 预防医学, 2019, 31(7): 649-652.
[11] 杨道余, 金亦荣, 洪仙月, 林上伟, 何凡, 古雪. 苍南县甲状腺癌危险因素的病例对照研究[J]. 预防医学, 2019, 31(4): 385-389.
[12] 朱婉红, 柳丽珍, 蔡仙国. 台州市膀胱癌危险因素的病例对照研究[J]. 预防医学, 2019, 31(3): 246-250.
[13] 姜莉萍, 王艳君. 子宫肌瘤发病影响因素的病例对照研究[J]. 预防医学, 2019, 31(10): 1061-1064.
[14] 余艳,陈燕,陈利坚,陈奇峰. 绍兴市冠心病急性事件发病分析[J]. 预防医学, 2018, 30(7): 723-724.
[15] 蒋晓霞, 陈坤, 杨梅, 陈恩平, 黄思远. 骨科手术患者术后感染危险因素的病例对照研究[J]. 预防医学, 2018, 30(3): 232-235,239.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed